{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Disorders", "query": { "condition": "Myotonic Disorders" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Disorders&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T14:21:14.187Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04886518", "title": "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myotonic Dystrophy 1", "Excessive Daytime Sleepiness" ], "interventions": [ { "name": "Pitolisant Oral Tablet", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harmony Biosciences Management, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2021-06-28", "completion_date": "2024-10-31", "has_results": true, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 11, "location_summary": "Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886518" }, { "nct_id": "NCT02398786", "title": "Myotonic Dystrophy Family Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy", "Congenital Myotonic Dystrophy", "Myotonic Dystrophy 1", "Myotonic Dystrophy 2", "Dystrophia Myotonica", "Dystrophia Myotonica 1", "Dystrophia Myotonica 2", "Myotonia Dystrophica", "Myotonic Dystrophy, Congenital", "Myotonic Myopathy, Proximal", "PROMM (Proximal Myotonic Myopathy)", "Proximal Myotonic Myopathy", "Steinert Disease", "Steinert Myotonic Dystrophy", "Steinert's Disease", "Myotonia Atrophica" ], "interventions": [ { "name": "Patient-entered data", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Myotonic Dystrophy Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3500, "start_date": "2013-02", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02398786" }, { "nct_id": "NCT07630389", "title": "Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy Type 1", "Congenital DM1", "Juvenile DM1", "Childhood DM1" ], "interventions": [], "intervention_types": [], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 100, "start_date": "2023-11-13", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630389" }, { "nct_id": "NCT01931644", "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "All Diagnosed Health Conditions", "ADD/ADHD", "Alopecia Areata", "Ankylosing Spondylitis", "Asthma", "Atopic Dermatitis Eczema", "Beta Thalassemia", "Bipolar Disorder", "Breast Cancer", "Celiac Disease", "Cervical Cancer", "Chronic Inflammatory Demyelinating Polyneuropathy", "Chronic Kidney Diseases", "Chronic Obstructive Pulmonary Disease", "Colon Cancer", "Colorectal Cancer", "Crohn's Disease", "Cystic Fibrosis", "Depression", "Diabetes Mellitus", "Duchenne Muscular Dystrophy", "Endometriosis", "Epilepsy", "Facioscapulohumeral Muscular Dystrophy", "G6PD Deficiency", "General Anxiety Disorder", "Hepatitis B", "Hereditary Hemorrhagic Telangiectasia", "HIV/AIDS", "Human Papilloma Virus", "Huntington's Disease", "Idiopathic Thrombocytopenic Purpura", "Insomnia", "Kidney Cancer", "Leukemia", "Lung Cancer", "Lupus Nephritis", "Lymphoma", "Melanoma", "Multiple Myeloma", "Multiple Sclerosis", "Myositis", "Myotonic Dystrophy", "Ovarian Cancer", "Pancreatic Cancer", "Parkinson's Disease", "Polycystic Kidney Diseases", "Prostate Cancer", "Psoriasis", "Psoriatic Arthritis", "Rosacea", "Scleroderma", "Sickle Cell Anemia", "Sickle Cell Trait", "Sjogren's Syndrome", "Skin Cancer", "Spinal Muscular Atrophy", "Systemic Lupus Erythematosus", "Thrombotic Thrombocytopenic Purpura", "Trisomy 21", "Ulcerative Colitis" ], "interventions": [], "intervention_types": [], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17667, "start_date": "2013-07", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931644" }, { "nct_id": "NCT06204809", "title": "Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myotonic Dystrophy 1" ], "interventions": [ { "name": "PGN-EDODM1 for infusion", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "PepGen Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2023-12-12", "completion_date": "2025-10-28", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 7, "location_summary": "Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06204809" }, { "nct_id": "NCT02251457", "title": "Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myotonia Congenita", "Paramyotonia Congenita", "Myotonic Dystrophy 1" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 35, "start_date": "2014-08", "completion_date": "2017-12-18", "has_results": false, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02251457" }, { "nct_id": "NCT07362875", "title": "Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2025-05-15", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07362875" }, { "nct_id": "NCT06089018", "title": "Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy 1" ], "interventions": [], "intervention_types": [], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "12 Years to 90 Years" }, "enrollment_count": 125, "start_date": "2022-09-10", "completion_date": "2024-09-10", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06089018" }, { "nct_id": "NCT01403402", "title": "Congenital Muscle Disease Study of Patient and Family Reported Medical Information", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)", "Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C))", "Alpha-Dystroglycanopathy (Fukuyama CMD)", "Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I))", "Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K))", "Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M))", "Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N))", "Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O))", "Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T))", "Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U))", "Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related)", "Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB))", "Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS))", "Choline Kinase B Receptor - CHKB", "Collagen VI Related Disorders", "Collagen XII Related Disorders", "Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive)", "Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID)", "Congenital Muscular Dystrophy With Joint Hyperlaxity", "Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1", "Emery-Dreifuss Muscular Dystrophy", "GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement", "LMNA Related Disorders", "Merosin Deficient CMD (Full or Partial)", "Nesprin Related MD (SYNE1)", "SELENON Related Disorders (Previously Known as SEPN1)", "SELENON Related Myopathy (Aka SEPN1)", "Telethonin CMD", "Congenital Myasthenic Syndrome", "Limb-Girdle Muscular Dystrophy", "LGMDD01 - DNAJB6 (Formerly LGMD1D)", "LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant)", "LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G)", "LGMDR08 - TRIM Related (Formerly LGMD2H)", "LGMDR09 - FKRP Related (Formerly LGMD2I)", "LGMDR10 - Titin (TTN) Related (Formerly LGMD2J)", "LGMDR11 - POMT1 Related (Formerly LGMD2K)", "LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M)", "LGMDR14 - POMT2 Related (Formerly LGMD2N)", "LGMDR15 - POMGnT1 Related (Formerly LGMD2O)", "LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P)", "LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q)", "LGMDR18 - TRAPPC11 Related (Formerly LGMD2S)", "LGMDR19 - GMPPB Related (Formerly LGMD2T)", "LGMDR20 - ISPD Related (Formerly LGMD2U)", "LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive)", "LGMDR23 - LAMA2 Related", "LGMDR24 - POMGnT2 Related" ], "interventions": [], "intervention_types": [], "sponsor": "Cure CMD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4000, "start_date": "2009-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403402" }, { "nct_id": "NCT05479981", "title": "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DM1", "Muscular Dystrophies", "Myotonic Dystrophy", "Myotonic Dystrophy 1", "Myotonic Disorders", "Muscular Disorders, Atrophic", "Muscular Diseases", "Musculoskeletal Diseases", "Neuromuscular Diseases", "Nervous System Diseases", "Genetic Diseases, Inborn", "Heredodegenerative Disorders, Nervous System", "Neurodegenerative Diseases" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AOC 1001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 37, "start_date": "2022-08-04", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-07-22T14:21:14.187Z", "location_count": 8, "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479981" } ] }